138 related articles for article (PubMed ID: 25044383)
21. Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin.
Eleftheriadis T; Pissas G; Remoundou M; Filippidis G; Antoniadi G; Oustampasidou N; Liakopoulos V; Stefanidis I
Int Urol Nephrol; 2014 Jan; 46(1):161-7. PubMed ID: 23860963
[TBL] [Abstract][Full Text] [Related]
22. Role of pentoxifylline in treatment of anemic patients suffering chronic hemodialysis: a randomized clinical trial.
Mortazavi M; Seyrafian S; Taheri S; Nasiri R; Dolatkhah S; Naini AE; Atapour A
Med Arh; 2012; 66(2):84-6. PubMed ID: 22486134
[TBL] [Abstract][Full Text] [Related]
23. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
24. Correlation between hepcidin level and renal anemia.
Yang LN; Zhang P; Tang F; Wang G; Li FE
Genet Mol Res; 2014 Sep; 13(3):7407-10. PubMed ID: 25222239
[TBL] [Abstract][Full Text] [Related]
25. Hepcidin and iron metabolism disorders in patients with chronic kidney disease.
Jelić M; Cvetković T; Djordjević V; Damnjanovć G; Vlahović P; Kocić G; Djindjić N; Jovović B; Antić A
Vojnosanit Pregl; 2013 Apr; 70(4):368-73. PubMed ID: 23700940
[TBL] [Abstract][Full Text] [Related]
26. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease.
Basseri RJ; Nemeth E; Vassilaki ME; Basseri B; Enayati P; Shaye O; Bourikas LA; Ganz T; Papadakis KA
J Crohns Colitis; 2013 Sep; 7(8):e286-91. PubMed ID: 23219355
[TBL] [Abstract][Full Text] [Related]
27. Hepcidin, iron indices and bone mineral metabolism in non-dialysis chronic kidney disease.
Min HK; Sung SA; Oh YK; Kim YH; Chung W; Park SK; Ahn C; Lee SW
Nephrol Dial Transplant; 2020 Jan; 35(1):147-154. PubMed ID: 30053139
[TBL] [Abstract][Full Text] [Related]
28. Preliminary experience on the use of sucrosomial iron in hemodialysis: focus on safety, hemoglobin maintenance and oxidative stress.
Reggiani F; Colombo G; Astori E; Landoni L; Finazzi S; Milzani A; Angelini C; Dalle-Donne I; Cucchiari D
Int Urol Nephrol; 2022 May; 54(5):1145-1153. PubMed ID: 34510284
[TBL] [Abstract][Full Text] [Related]
29. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
[TBL] [Abstract][Full Text] [Related]
30. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
[TBL] [Abstract][Full Text] [Related]
31. Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease.
Mecklenburg I; Reznik D; Fasler-Kan E; Drewe J; Beglinger C; Hruz P;
J Crohns Colitis; 2014 Nov; 8(11):1392-7. PubMed ID: 24825446
[TBL] [Abstract][Full Text] [Related]
32. Association between hepcidin, haemoglobin level and iron status in stage 4 chronic kidney disease patients with anaemia.
Mogadam RA; Nemati A; Amani F; Ghorbanihaghjo A; Argani H; Bashardoust B
J Pak Med Assoc; 2015 Apr; 65(4):354-7. PubMed ID: 25976565
[TBL] [Abstract][Full Text] [Related]
33. Serum hepcidin levels are associated with serum triglycerides and interleukin-6 concentrations in patients with end-stage renal disease.
Samouilidou E; Pantelias K; Petras D; Tsirpanlis G; Bakirtzi J; Chatzivasileiou G; Tzanatos H; Grapsa E
Ther Apher Dial; 2014 Jun; 18(3):279-83. PubMed ID: 24119290
[TBL] [Abstract][Full Text] [Related]
34. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
35. Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients.
Ibricevic-Balic L; Icindic-Nakas E; Hasic S; Kiseljakovic E; Sofo-Hafizovic A; Balic S
Med Arch; 2016 Dec; 70(6):429-432. PubMed ID: 28210014
[TBL] [Abstract][Full Text] [Related]
36. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
37. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
38. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
39. Relationship between hepcidin and GDF15 in anemic patients with type 2 diabetes without overt renal impairment.
Hong JH; Choi YK; Min BK; Park KS; Seong K; Lee IK; Kim JG
Diabetes Res Clin Pract; 2015 Jul; 109(1):64-70. PubMed ID: 25998917
[TBL] [Abstract][Full Text] [Related]
40. Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency.
Sultana T; DeVita MV; Michelis MF
Int Urol Nephrol; 2016 Sep; 48(9):1519-24. PubMed ID: 27170339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
